Skip to content

A randomized controlled trial to determine the effect of increase curative rate and decrease recurrence rate of Bushen Shengxue and Nourishing 'Qi' method in the treatment of aplastic anemia

A randomized controlled trial to determine the effect of increase curative rate and decrease recurrence rate of Bushen Shengxue and Nourishing 'Qi' method in the treatment of aplastic anemia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16009834
Enrollment
Unknown
Registered
2016-11-12
Start date
2017-08-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

aplastic anemia

Interventions

Kidney deficiency group:taking Bushen Shengxue prescription
deficiency of Qi and blood group:taking Yiqi Yangxue formula
control group:taking half of kidney nourishing blood

Sponsors

Xiyuan Hospital affiliated to China Academy of Traditional Chinese Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. with Aplastic Anemia Diagnosis; kidney deficiency and blood deficiency type with two standard; 2. Aged 14 years to 80 years; liver and kidney function is normal; hemoglobin <80g/L; 3. Course of disease in 1 years or more in the course of more than half a year, but did not receive regular treatment; 4. did not participate in other clinical research.

Exclusion criteria

Exclusion criteria: 1. Other diseases that cause the reduction of whole blood cells, such as paroxysmal nocturnal hemoglobin, bone marrow hyperplasia, acute blood stasis, and bone marrow fibrosis; 2. Congenital aplastic anemia, congenital; 3. Patients with serious heart, brain, liver, kidney disease and mental disease; 4. The pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
Routine blood test;Bone marrow routine;

Secondary

MeasureTime frame
CD3+CD19-;CD3+CD4+CD8-;Th1/Th2;CD3+CD4+CD8+;CD3+CD4-CD8+;CD3+DR+;CD3+CD25+;T-bet/GATA-3 gene;Urine, stool routine, stool OB;B ultrasound (liver, gallbladder, spleen, pancreas, double kidney), electrocardiogram;Liver and kidney function;

Countries

China

Contacts

Public ContactLiu Feng

Xiyuan Hospital affiliated to China Academy of Traditional Chinese Sciences

liufengdoctor@126.com+86 13701249039

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026